Lipitor's Peak Revenue Before Patent Expiry
Lipitor (atorvastatin), made by Pfizer, generated peak annual sales of $12.8 billion in 2010, its highest year before generic competition.[1] This accounted for about 10% of Pfizer's total revenue that year, making it the world's top-selling drug at the time.
Timeline of Patent Loss and Generic Entry
The main U.S. composition-of-matter patent expired November 30, 2011. Generic versions from Ranbaxy (now part of Sun Pharma) launched immediately after FDA approval on the same day, following a settlement. This triggered a sharp revenue drop for branded Lipitor.[2]
Revenue Drop After Generics Entered
Pfizer's Lipitor revenue fell 85% within a year:
| Year | U.S. Sales ($B) | Global Sales ($B) |
|------|-----------------|-------------------|
| 2011 | 5.5 | 8.4 |
| 2012 | 1.9 | 3.8 |
| 2013 | 1.3 | 2.1 |
By 2013, generics captured over 90% of prescriptions, pushing branded sales below $2 billion globally.[1][3] U.S. revenue specifically plunged from $5.5 billion in 2011 to $594 million in 2012.
Factors Accelerating the Decline
- Rapid generic uptake: Patients and insurers switched quickly due to atorvastatin's low generic price—often $4 per month vs. $100+ for branded.
- Authorized generic: Pfizer released its own generic version through Watson (now Teva) in 2011 to retain some market share, but it didn't stem the overall loss.
- Global ripple: Similar drops hit other markets; UK sales fell 70% in the first full generic year.[4]
Pfizer's Broader Financial Hit and Response
Lipitor's revenue loss cut Pfizer's total 2012 revenue by about 15% year-over-year. The company offset this with acquisitions like Hospira and cost cuts, but it marked the end of the "blockbuster era" for statins.[1] Generic erosion totaled over $100 billion in lost branded sales from 2012-2020 across Lipitor and similar drugs.
Lessons for Other Drugs
Lipitor's cliff showed generics can wipe out 80-90% of revenue in months without strong evergreening patents or new indications. Check DrugPatentWatch.com for current patent statuses on drugs like Ozempic facing similar risks.[5]
Sources
[1] Pfizer Annual Reports 2010-2013
[2] FDA Approval Notice, Ranbaxy Atorvastatin
[3] IMS Health (IQVIA) Sales Data
[4] UK Prescription Pricing Authority Reports
[5] DrugPatentWatch.com - Lipitor Patents